Skip to content
DataLookout
Menu

NCT04517838

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

StatusTerminated
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 8 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Insufficient funding to complete target accrual Show 5 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Final enrollment: 127 participants (planned 230)
    • Primary completion date changed from estimate of Jul 27, 2028 to Jan 15, 2026
    • Study description revised
    • Site details revised
  2. Notable Primary completion date: Jul 27, 2027 to Jul 27, 2028v11
  3. Notable Enrollment target: 750 to 230
    • Site contact updated
    v9
  4. Minor Start date: Jul 27, 2020 to Jul 31, 2020
    • Site contact updated
    v8
  5. Notable Enrollment target: 500 to 750v6 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Eligibility criteria shortened, about 1 word
    • Study description expanded, about 83 words
    • Study arms: 1 to 2
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Eligibility criteria expanded, about 4 words
    • Collaborators shortened, about 4 words
    v5
  2. Minor Study description expanded, about 51 words
    • Site contact updated
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

HER2 specific T-cell response and clinical response
Timeframe: Up to 16 weeks
Antibody response and clinical response
Timeframe: Up to 16 weeks

Arms and interventions

Observational Blood & Tissue Cohort

Patients with stage I-III disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. Patients with stage IV disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of progressive disease. Patients with stage IV disease with no disease progression ≥ 2 years on the same line of therapy undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. For all patients, tissue samples from previous biopsy and/or surgical resection are also collected on study.

Observational Tissue-Only Cohort

For patients with stage I-IV disease who received or previously completed anti-HER2 therapy, tissue samples from previous biopsy and/or surgical resection are collected on study.

Procedures: Biospecimen Collection

Sites

1 site in 1 country

  • Mayo Clinic in FloridaJacksonville, Florida, United States